Publications by authors named "You-Bing Zheng"
γδ T cells are one of only three immune cell types that express antigen receptors that undergo somatic recombination, and they contribute to immune responses to infection, cellular transformation, and tissue damage. As a "bridge" between the innate and adaptive immune systems, γδ T cells have been noted to be involved in various immune responses during cancer progression. The purpose of our study was to review current published information on γδ T cells and investigate their functions in different types of malignancy using bibliometric and bioinformatic methods.
View Article and Find Full Text PDFObjectives: It was the aim of this study to find an optimal therapeutic regimen of transarterial chemoembolization (TACE) by comparing the efficacy of chemoembolization with different anticancer agents in hepatocellular carcinoma (HCC) patients.
Methods: A single-blind, three-group parallel, randomized trial was conducted in Guangdong General Hospital, Guangzhou, China, with patients with biopsy-confirmed HCC. Group 1 received single-drug (doxorubicin) chemoembolization, while group 2 received double-drug (doxorubicin and mitomycin C) chemoembolization.
Aim: To evaluate the efficacy and safety of arsenic trioxide transarterial chemoembolization and intravenous administration in unresectable hepatocellular carcinoma with lung metastasis.
Methods: A single-blind, two-parallel group, randomized trial was conducted at three medical centers (Guangzhou, China), including patients with both biopsy-confirmed hepatocellular carcinoma and lung metastasis. The experimental group received arsenic trioxide transarterial chemoembolization and intravenous administration of arsenic trioxide, while the control group only received arsenic trioxide transarterial chemoembolization.
Article Synopsis
- KDR is a key receptor involved in promoting blood vessel growth and is a target for treatments aimed at inhibiting angiogenesis; this study investigates the impact of genetic variations (SNPs) in the KDR gene on treatment outcomes for advanced liver cancer patients.
- In a study of 78 patients on first-line sorafenib therapy, specific KDR genotypes (AA in rs1870377 and rs2305948) were linked to better treatment responses and longer time to disease progression.
- The findings indicate that certain SNPs in the KDR gene could serve as biomarkers to predict survival outcomes in advanced hepatocellular carcinoma patients undergoing sorafenib therapy.
Article Synopsis
- The study aimed to see if counting circulating tumor cells (CTCs) can indicate how effective transarterial chemoembolization (TACE) is after surgery for liver cancer.
- Conducted on 171 patients with hepatocellular carcinoma, the trial compared a TACE group with a control group that didn't receive treatment after surgery.
- Results showed that the TACE group had significantly lower CTC counts and a lower recurrence rate of cancer compared to the control group, suggesting that CTC counts can serve as a useful marker for predicting cancer recurrence after treatment.
Article Synopsis
- KDR is a key receptor that facilitates blood vessel formation and is linked to the development of various cancers, especially hepatocellular carcinoma (HCC).
- This study assessed the relationship between specific genetic variations (SNPs) in the KDR gene and clinical outcomes for 192 HCC patients undergoing a specific treatment called transcatheter arterial chemoembolization.
- Findings revealed that certain genotypes of KDR SNPs (rs1870377 and rs2071559) were significantly associated with better overall survival rates, suggesting they could serve as important prognostic indicators for HCC patients.
Article Synopsis
- * A significant decrease (over 10%) in serum VEGFR2 levels after treatment was seen in 26% of patients and was linked to longer median survival times (19.0 vs. 9.8 months).
- * Besides VEGFR2 response, factors like extrahepatic metastases and vascular invasion also impacted overall survival, with VEGFR2 decrease being an independent predictor.
Article Synopsis
- This study examines how the neutrophil-to-lymphocyte ratio (NLR) relates to survival outcomes in advanced hepatocellular carcinoma (HCC) patients receiving sorafenib treatment.
- It involved 65 patients, revealing that those with high NLR (>4) had significantly shorter overall survival (OS) and time to progression (TTP) compared to those with normal NLR (≤4).
- The findings suggest that a high baseline NLR is an important predictor of poorer prognosis in these patients, along with other factors like age, vascular invasion, and extrahepatic metastases.
Article Synopsis
- This study evaluates the effectiveness and safety of using sorafenib in combination with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for treating patients with unresectable hepatocellular carcinoma (HCC).
- The findings indicate a disease control rate of 33.3%, with a median time to progression of 15.3 months and median overall survival of 28.8 months.
- Common side effects of sorafenib included hand-foot skin reactions (53.3%) and diarrhea (33.3%), showing that the treatment combination is both safe and effective for patients.